Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Diurnal Group plc (DNL) Ordinary 5p

Sell:33.00p Buy:36.00p 0 Change: 4.50p (15.00%)
Market closed Prices as at close on 15 October 2019 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:33.00p
Buy:36.00p
Change: 4.50p (15.00%)
Market closed Prices as at close on 15 October 2019 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:33.00p
Buy:36.00p
Change: 4.50p (15.00%)
Market closed Prices as at close on 15 October 2019 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company's products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism. The Company's products are under various clinical trials, including Chronocort, which is in Phase III clinical trial; Infacort, which is in Phase III clinical trial, and Native Oral Testosterone, which is in Phase I clinical trial.

Contact details

Address:
Heath Park
CARDIFF
CF14 4UJ
United Kingdom
Telephone:
+44 (029) 20682069
Website:
www.diurnal.co.uk/

Important dates

Future events
AGM 21 November 2019 21/11/19
Past events
Annual report 08 October 2019 08/10/19
Final results 24 September 2019 24/09/19
Interim results 28 March 2019 28/03/19

General stock information

EPIC:
DNL
ISIN:
GB00BDB6Q760
Market cap:
£29.20 million
Shares in issue:
84.64 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Martin Whitaker
    Chief Executive Officer, Executive Director
  • Richard Bungay
    Chief Financial Officer
  • Richard Ross
    Chief Scientific Officer, Director
  • David Eckland
    Medical Director
  • Hiep Huatan
    Chief Development Offer
  • Daniel Nelson Margetson
    CMC Director
  • John Porter
    Medical Affairs Director
  • Michael Withe
    Commercial Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.